Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk

StatusCompleted
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Primary completion date changed from estimate of Sep 2026 to Dec 7, 2025
    • Eligibility criteria expanded, about 9 words
    • Publications: details revised at 1 of 1 entry
  2. Primary completion date: Sep 2025 to Sep 2026
    • Study completion date: Dec 2025 to Dec 2026
    v21
  3. Primary completion date: Sep 2024 to Sep 2025
    • Study completion date: Dec 2024 to Dec 2025
    v20
  4. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v19
  5. Primary completion date: Sep 2023 to Sep 2024
    • Study completion date: Dec 2023 to Dec 2024
    v18
Show 16 earlier versionsHide 16 earlier versions
  1. Publications: details revised at 1 of 1 entryv17
  2. Re-verified, no change to tracked fieldsv16
  3. Eligibility criteria shortened, about 24 words
    • Secondary endpoints: details revised at 1 of 11 entries
    v15
  4. Trial status: Active, Not Recruiting to Recruitingv14 Show 6 more changesShow less
    • Primary completion date: Sep 2020 to Sep 2023
    • Study completion date: Dec 2020 to Dec 2023
    • Eligibility criteria expanded, about 152 words
    • Secondary endpoints: 2 to 11
    • Site details revised
    • Study arms: 4 to 6
  5. Phase: Not specified to Not applicablev13 Show 4 more changesShow less
    • Primary completion date: Sep 2019 to Sep 2020
    • Study completion date: Sep 2020 to Dec 2020
    • Interventions: Weight loss (Other)
    • Study title shortened, about 1 word
  6. Primary completion date: Apr 2019 to Sep 2019
    • Study completion date: Apr 2020 to Sep 2020
    v12
  7. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v11
  8. Primary completion date: Apr 2017 to Apr 2019
    • Study completion date: Apr 2018 to Apr 2020
    v10
  9. Primary completion date: Apr 2016 to Apr 2017
    • Study completion date: Apr 2017 to Apr 2018
    • Secondary endpoints: details revised at 2 of 2 entries
    • Primary endpoint revised
    v9
  10. Re-verified, no change to tracked fieldsv8
  11. Enrollment target: 36 to 144
    • Study arms: 3 to 4
    • Study title shortened, about 1 word
    v7
  12. Primary completion date: Apr 2015 to Apr 2016
    • Study completion date: Apr 2016 to Apr 2017
    v6
  13. Primary completion date: Apr 2014 to Apr 2015
    • Study completion date: Apr 2015 to Apr 2016
    v5
  14. Primary completion date: Apr 2012 to Apr 2014
    • Study completion date: Apr 2014 to Apr 2015
    v4
  15. 2 versions Re-verified since Dec 10, 2010, no change to tracked fieldsv2-v3
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to learn more about how the body stores fat in and around organs (for example in the liver) and why this affects some people's health more than others. Understanding this may lead to better treatments for diseases such as diabetes and cardiovascular disease.
Trial Details
NCT Number NCT01104220
Lead Sponsor Washington University School of Medicine
Collaborators: Pfizer
Conditions
(from sponsor)		 Non-alcoholic Fatty Liver Disease, Metabolic Syndrome, Metabolically Abnormal Obesity, Metabolically Normal Obesity, Obesity
Related terms Metabolic Syndrome, Non-alcoholic Fatty Liver Disease, Obesity
Enrollment 144 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov